Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 10/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 10/20 | 0.55 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.52 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063051 | 0.85 | HRH3 (0.57) | L3MBTL3L3MBTL1MBTD1HRH3SMN1; SMN2 | |
| SCHEMBL3183618 | 0.84 | HRH3 (0.60) | L3MBTL3L3MBTL1MBTD1HRH3SMN1; SMN2 | |
| SCHEMBL4058468 | 0.82 | HRH3 (0.52) | L3MBTL3L3MBTL1MBTD1HRH3SMN1; SMN2 | |
| SCHEMBL4056900 | 0.82 | HRH3 (0.59) | HRH3ALDH1A1 | |
| SCHEMBL10264415 | 0.78 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL13222431 | 0.77 | L3MBTL3 (0.63) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL3194408 | 0.77 | LMNA (0.56) | HRH3ALDH1A1 | |
| SCHEMBL477889 | 0.76 | HRH3 (0.57) | HRH3SMN1; SMN2ALDH1A1 | |
| SCHEMBL3857989 | 0.75 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 | |
| SCHEMBL15759135 | 0.75 | L3MBTL3 (0.65) | L3MBTL3L3MBTL1MBTD1TP53BP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | claimed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | claimed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | claimed |
| EP-1492785-B9 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2009-10-21 | — | — | EP | disclosed |
| US-20090149460-A1 | New Compounds | BERG STEFAN | 2009-06-11 | — | — | US | disclosed |
| EP-1492785-B1 | 2-HYDROXY-3-HETEROARYLINDOLE DERIVATIVES AS GSK3 INHIBITORS | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1961748-A2 | 2-hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7399780-B2 | 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3 | ASTRAZENECA AB (SE) | 2008-07-15 | — | — | US | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149460-A1 | New Compounds | SDHA, CYP11B2, SERPINB1 | L3MBTL3 4885/4885L3MBTL1 4876/4885MBTD1 4340/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | L3MBTL3 4883/4885L3MBTL1 4869/4885MBTD1 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.